International Clinical Neuroscience Journal

Vol. 8 No. 1 (2021)

Effectiveness of Autologous Schwann Cell and Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Individuals With Spinal Cord Injury in Promoting Sensory Recovery

International Clinical Neuroscience Journal, Vol. 8 No. 1 (2021), 30 December 2020 , Page 9-13

Abstract

Background: In recent decades, improvement in sensory and motor function after spinal cord injury
(SCI) is a major treatment goal. Stem cell therapy has become a promising treatment strategy in the
regeneration of central nervous system injuries.
Methods: We assessed the effectiveness of autologous Schwann cell (SC) and bone marrow-derived
mesenchymal stem cell (MSC) for individuals with SCI in promoting sensory recovery. Five patients
with a mean ± SD age of 38.80 ± 5.84 years were enrolled in the study. The follow-up course was
12 months.
Results: We found sensory changes in two patients assessed by the American Spinal Injury
Association’s (ASIA’s) impairment scale. Systemic complications were not observed during the
course of the study.
Conclusion: There were no adverse finding after cell transplantation. Also we observed improvement
in sensory score in two patients. It seems that the use of this combination of cell therapy may be
effective; but large group studies with control group are required to clarify the effect of either cells.

Keywords:
  • Schwann cell
  • Bone marrow
  • Mesenchymal stem cell
  • Spinal cord injury
  • Sensory recovery

How to Cite

1.
Golmohammadi M, Akhlaghpasand M, Oraee-Yazdani S, Zali A. Effectiveness of Autologous Schwann Cell and Bone Marrow-Derived Mesenchymal Stem Cell Transplantation for Individuals With Spinal Cord Injury in Promoting Sensory Recovery. Int Clin Neurosci J [Internet]. 2020 Dec. 30 [cited 2024 Dec. 11];8(1):9-13. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/33110

References

Willison AG, Smith S, Davies BM, Kotter MR, Barnett SC. A scoping review of trials for cell-based therapies in human spinal cord injury. Spinal Cord. 2020:1-13.

Wyndaele M, Wyndaele J-J. Incidence, prevalence and epidemiology of spinal cord injury: what learns a worldwide literature survey? Spinal cord. 2006;44(9):523-9.

Bond AM, Ming G-l, Song H. Adult mammalian neural stem cells and neurogenesis: five decades later. Cell stem cell. 2015;17(4):385-95.

Malgieri A, Kantzari E, Patrizi MP, Gambardella S. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. International journal of clinical and experimental medicine. 2010;3(4):248.

Saberi H, Moshayedi P, Aghayan H-R, Arjmand B, Hosseini S-K, Emami-Razavi S-H, et al. Treatment of chronic thoracic spinal cord injury patients with autologous Schwann cell transplantation: an interim report on safety considerations and possible outcomes. Neuroscience letters. 2008;443(1):46-50.

Thomspon M, Wolfe D, Champagne J, Mei S, Lalu M, Fergusson D, et al. Safety of cell therapy with mesenchymal stromal cells): An updated systematic review and meta-analysis of randomized controlled trials (safecell update). Cytotherapy. 2018;20(5):S53-S4.

Liau LL, Looi QH, Chia WC, Subramaniam T, Ng MH, Law JX. Treatment of spinal cord injury with mesenchymal stem cells. Cell & Bioscience. 2020;10(1):1-17.

Oraee-Yazdani S, Hafizi M, Atashi A, Ashrafi F, Seddighi A, Hashemi S, et al. Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome. Spinal Cord. 2016;54(2):102-9.

Yazdani SO, Hafizi M, Zali A-R, Atashi A, Ashrafi F, Seddighi A-S, et al. Safety and possible outcome assessment of autologous Schwann cell and bone marrow mesenchymal stromal cell co-transplantation for treatment of patients with chronic spinal cord injury. Cytotherapy. 2013;15(7):782-91.

McCreedy DA, Sakiyama-Elbert SE. Combination therapies in the CNS: engineering the environment. Neuroscience letters. 2012;519(2):115-21.

Xu P, Yang X. The efficacy and safety of mesenchymal stem cell transplantation for spinal cord injury patients: a meta-analysis and systematic review. Cell transplantation. 2019;28(1):36-46.

Yoon SH, Shim YS, Park YH, Chung JK, Nam JH, Kim MO, et al. Complete spinal cord injury treatment using autologous bone marrow cell transplantation and bone marrow stimulation with granulocyte macrophage‐colony stimulating factor: phase I/II clinical trial. Stem cells. 2007;25(8):2066-73.

Bhanot Y, Rao S, Ghosh D, Balaraju S, CR R, KV SK. Autologous mesenchymal stem cells in chronic spinal cord injury. British journal of neurosurgery. 2011;25(4):516-22.

Schaal S, Kitay B, Cho K, Lo Jr T, Barakat D, Marcillo A, et al. Schwann cell transplantation improves reticulospinal axon growth and forelimb strength after severe cervical spinal cord contusion. Cell transplantation. 2007;16(3):207-28.

Kakabadze Z, Kipshidze N, Mardaleishvili K, Chutkerashvili G, Chelishvili I, Harders A, et al. Phase 1 trial of autologous bone marrow stem cell transplantation in patients with spinal cord injury. Stem cells international. 2016;2016.

Jiang P-C, Xiong W-P, Wang G, Ma C, Yao W-Q, Kendell SF, et al. A clinical trial report of autologous bone marrow‑derived mesenchymal stem cell transplantation in patients with spinal cord injury. Experimental and therapeutic medicine. 2013;6(1):140-6.

  • Abstract Viewed: 317 times
  • PDF Downloaded: 367 times

Download Statastics